| 5.04 -0.52 (-9.35%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.05  |
1-year : | 7.84 |
| Resists | First : | 6.03 |
Second : | 6.71 |
| Pivot price | 5.86 |
|||
| Supports | First : | 4.92 |
Second : | 4.1 |
| MAs | MA(5) : | 5.65 |
MA(20) : | 5.97 |
| MA(100) : | 5.99 |
MA(250) : | 5.27 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 26.6 |
D(3) : | 38.6 |
| RSI | RSI(14): 30.4 |
|||
| 52-week | High : | 7.77 | Low : | 1.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SLN ] has closed below the lower bollinger band by 16.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.6 - 5.63 | 5.63 - 5.66 |
| Low: | 4.86 - 4.9 | 4.9 - 4.93 |
| Close: | 4.99 - 5.05 | 5.05 - 5.09 |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Sat, 10 Jan 2026
Silence Therapeutics Insider Ups Holding During Year - simplywall.st
Sat, 10 Jan 2026
Silence Therapeutics Insider Ups Holding During Year - Sahm
Mon, 22 Dec 2025
Silence Therapeutics Appoints CFO Rhonda Hellums to Board - TipRanks
Sun, 21 Dec 2025
With 35% ownership, Silence Therapeutics plc (NASDAQ:SLN) insiders have a lot at stake - Yahoo Finance
Mon, 15 Dec 2025
Silence Therapeutics CEO Craig Tooman steps down - Investing.com
Mon, 15 Dec 2025
Silence Therapeutics (Nasdaq: SLN) names chair interim CEO, adds board member - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 7.475e+007 (%) |
| Held by Institutions | 24.3 (%) |
| Shares Short | 922 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.941e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -249.9 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 881.1 % |
| Return on Equity (ttm) | -23.4 % |
| Qtrly Rev. Growth | 2.583e+007 % |
| Gross Profit (p.s.) | -66.72 |
| Sales Per Share | -47.99 |
| EBITDA (p.s.) | 1.76045e+007 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -72 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 4.3 |
| Dividend | 0 |
| Forward Dividend | 1.12e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|